开发了一种灭活的SARS-CoV-2候选疫苗BBIBP-CorV; BBIBP-CorV在动物模型中诱导产生了高浓度的中和性抗体; 2次注射该疫苗(2 ug/次)可以保护恒河猴免受SARS-CoV-2感染; SARS-CoV-2可以高效生产,基因较稳定,同时在动物实验中看起来是安全的。 在这项研究中,研究人员报道了一种灭活的SARS-CoV-2候选疫苗(BBIBP-C...
[COVID-19]), and vaccine-induced humoral immunogenicity (SARS-CoV-2 neutralizing antibody,anti-nucleocapsid IgG, andanti-spike IgG) of the Sinopharm (BBIBP-CorV) vaccine among people with MS (PwMS) receiving different disease-modifying therapies (DMTs).#This prospective cohort study was conducted...
This open-label phase 1/2 study was conducted in healthy Thai adults aged ≥ 18 years who had completed primary BBIBP-CorV primary vaccination between 90–240 (Arm A1; n = 361) or 45–75 days (Arm A2; n = 104) before enrolment. All received an Ad26.COV2.S booster. We measured an...
What similarities were noted between the findings of this trial and those of a similar trial on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) vaccines? What were the findings regarding the safety and tolerability of the BBIBP-CorV vaccine in different age groups? What specific test...
新西兰政府目前认可7种中国疫苗·安徽智飞新冠疫苗(ZF2007)·克威莎新冠疫苗(Ad5-nCoV)·高端新冠疫苗(MVC-COV1901) ·深圳康泰新冠疫苗(SARS-CoV-2 Vaccine (Vero Cells))·国药北京生物众爱可维新冠疫苗(BBIBP-CorV (Vero Cells))·国药武汉生物新冠疫苗(Inactivated (Vero Cells))·科兴新冠疫苗(Sinovac CoronaVa...
总而言之,这项临床试验的结果显示:灭活SARS-CoV-2疫苗BBIBP-CorV在中青年(18-59岁)、老年(≥60岁)两个年龄段的所有测试剂量下均安全且耐受性良好。在第42天能在所有疫苗接种者中诱导出针对SARS-CoV-2的体液应答。在第0天和第21天或第0天和第28天用4μg疫苗进行两剂免疫接种的中和抗体效价高于单剂8μg或...
SARS-CoV-2COVID-19 vaccinescancer patientsanticancer treatmentMalignancyObjective To evaluate the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine in cancer patients.Material and method 364 cancer patients who received two doses of vaccine were enrolled. The presence of SARS-CoV-2 ...
Here we show a registered observational clinical trial (NCT04795414), we assess the safety and immunogenicity of the inactivated SARS-CoV-2 vaccine BBIBP-CorV in a cohort of 1006 vaccine recipients. No serious adverse events are observed during the term of the study. Detectable virus-specific ...
Yet, so far, no study has reported the effects of inactivated SARS-CoV-2 virus vaccines on gut microbiota alterations. In this study, we examined the effects of the BBIBP-CorV vaccine (ChiCTR2000032459, sponsored by the Beijing Institute of Biological Products/Sinopharm), on gut microbiota. ...
In general, the current study did not observe the protective effect of CoronaVac and BBIBP CorV against BA.5.2 and BF.7 infection. However, these vaccines can still reduce the risk of adverse outcomes such as pneumonia and hospitalization....